cece

*May 2021* Note: Is further evaluation of the combination warranted for patients with locally advanced or metastatic T790M-negative, EGFR-positive NSCLC? The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation…

*July 2021* Note  Should a VEGF inhibitor (bevacizumab/Avastin) be combined with osimertinib or not? The role of osimertinib combinations as second-line treatment for advanced non-small cell lung cancer (NSCLC) is still unclear, according to researchers. Osimertinib is a standard first-line treatment option for patients with advanced NSCLC and EGFR mutations, but progression on this…

*ASCO 2021* Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation tyrosine kinase inhibitor, in both treatment-naïve and osimertinib (osi)-relapsed patients (pts) with EGFRm NSCLC (Cho Ann Oncol 2020;31:S813). We present updated results of the combination in osi-relapsed pts, including an…

*June 2021* — Patients harboring these uncommon mutations may need "special selection of EGFR TKIs" EGFR mutations in non-small cell lung cancer (NSCLC) were first pinpointed in 2004. These mighty mutations have emerged as the strongest predictor of response to EGFR tyrosine kinase inhibitor (TKI) therapies, with deletions in exon 19 and the point…

*ASCO 2021* Note: Could this become a less-expensive alternative to osimertinib? Background: Au is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. Au has been approved in China for treatment of patients (pts)…

*June 2021* Note: The CHRYSALIS Trial, involves a combination of amivantamab and lazertinib in patients with Tagrisso-relapsed and chemo naïve cancer. Alexander Spira, MD, PhD, FACP, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program, discusses the updated results of the…

*April 2021* Note: This trial indicates that this might be a good treatment for post-Tagrisso progression, even in heavily pre-treated patients. Dr. Pasi Jänne shares updated phase 1 data on the antibody–drug conjugate patritumab deruxtecan in advanced EGFR-mutated non-small-cell lung cancer patients who have developed resistance to EGFR inhibitors. Watch…

*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symptomatic response to systemic pemetrexed in combination with osimertinib. This builds on the limited data evaluating…